Plain-English translation of NCT06007690 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment called belzupacap sarotalocan (AU-011) that is injected directly into the space behind the eye using a special microinjector. Once injected, a laser activates the medication to help shrink small melanomas or uncertain lesions on the back of the eye. Researchers want to compare two different doses of this medication against a sham (fake) treatment to see which works best and is safest.
Small melanomas and uncertain lesions on the back of the eye can be hard to treat, and current options may cause vision loss. This trial exists to see whether the new treatment can effectively shrink these tumors while preserving sight better than existing approaches.
You will be randomly assigned to receive either a high-dose injection, a low-dose injection, or a sham (fake) injection, all combined with laser activation. Neither you nor the research team will know which treatment you receive, which helps ensure fair results. You will need to attend study visits to monitor your eye and overall health, and the research team will use imaging to track whether the lesion shrinks over time.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States